Literature DB >> 28112790

Atenolol treatment for infantile haemangioma.

M Tasani1, M Glover1, A E Martinez1, L Shaw1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28112790     DOI: 10.1111/bjd.15317

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.

Authors:  Jillian G Baker; Christophe Fromont; Marjorie Bruder; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Sheila M Gardiner; Peter M Fischer
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

2.  Oral Atenolol versus Propranolol in the Treatment of Infantile Hemangioma: A Systematic Review and Meta-Analysis.

Authors:  Swapnil Annasaheb Pattanshetti; Vidya M Mahalmani; Phulen Sarma; Hardeep Kaur; Md Mokkaram Ali; Muneer Abas Malik; Nitin James Peters; Manisha Prajapat; Subodh Kumar; Bikash Medhi; Ram Samujh
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-05-12

3.  Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients.

Authors:  Ze-Liang Zhao; Chao Liu; Qi-Zhang Wang; Hai-Wei Wu; Jia-Wei Zheng
Journal:  Ann Transl Med       Date:  2021-01

4.  A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas.

Authors:  Ze-Liang Zhao; Chao Liu; Qi-Zhang Wang; Wen-Bo Zhang; Lu Shao; Hai-Wei Wu; Jia-Wei Zheng
Journal:  Medicine (Baltimore)       Date:  2021-01-08       Impact factor: 1.817

5.  Cost-effectiveness of atenolol compared to propranolol as first-line treatment of infantile haemangioma: A pilot study.

Authors:  Sasha Wilson; Deniz Hassan; Molly Jakeman; Eleonore Breuning
Journal:  JPRAS Open       Date:  2022-05-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.